11 completed, 6 active not recruiting, 6 unknown, 5 recruiting. 13 Phase 2, 11 Phase 1, 6 Not applicable, 3 Phase 3, 3 Phase 4.
Follow Medullary Thyroid Cancer: new trials by email Literature Review of Medullary Thyroid Cancer trials Research Report on Medullary Thyroid Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 211At-MABG in Adults With Advanced Neuroendocrine Cancers 1 MBq/k of 211At-MABG Fractionated, 2 MBq/k1 of 211At-MABG Fractionated, 4 MBq/k of 211At-MABG Fractionated - Pheochromocytoma, Paraganglioma | Phase 1 | Not yet recruiting | University of Pennsylvania | 16 | 2026-12-01 | 2026-10-07 |
| Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy - Melanoma, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Recruiting | University of Arizona | 30 | 2025-09-08 | 2026-10-06 |
| A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study Medullary Thyroid Cancer | Not yet recruiting | Power Life Sciences Inc. | 500 | 2024-11-01 | 2023-10-12 | |
| Predictive Factors for Medullary Thyroid Cancer Aggressiveness Total Thyroidectomy - Medullary Thyroid Cancer | Completed | Aristotle University Of Thessaloniki | 500 | 2024-03-01 | 2025-01-03 | |
| Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) individualized mRNA neoantigen vaccine (mRNA-0523-L001) - Adrenal Cortical Carcinoma, Medullary Thyroid Cancer | Not applicable | Recruiting | Shanghai Jiao Tong University School of Medicine | 21 | 2024-01-13 | 2026-04-09 |
| A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). Pralsetinib, Cabozantinib, Vandetanib - Medullary Thyroid Cancer | Phase 3 | Withdrawn | Hoffmann-La Roche | 2023-11-30 | 2024-01-05 | |
| 68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC Surgery - Medullary Thyroid Cancer, Prositron Emission Tomography | Not applicable | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 50 | 2023-10-01 | 2024-02-26 |
| Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma Anlotinib Hydrochloride Capsule - Medullary Thyroid Cancer | Phase 4 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 360 | 2023-06-19 | 2023-07-25 |
| A Study of TY-1091 in Patients With Advanced Solid Tumors TY-1091 - RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Unknown | TYK Medicines, Inc | 248 | 2023-04-24 | 2024-01-30 |
| Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer 18F-PSMA-1007 - Medullary Thyroid Cancer, Medullary Thyroid Carcinoma | Not applicable | Completed | University Medical Center Groningen | 8 | 2022-08-19 | 2025-06-24 |
| Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients Neuroendocrine Neoplasm, Neuroendocrine Neoplasm of Gastrointestinal Tract | Recruiting | Universidad Nacional Autonoma de Mexico | 750 | 2022-08-03 | 2024-07-26 | |
| Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor SY-5007 - Non-Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Unknown | Shouyao Holdings (Beijing) Co. LTD | 184 | 2021-04-23 | 2023-04-12 |
| Amyloid Proteins From Medullary Thyroid Cancer and Laryngeal Amyloidosis Amyloid, Medullary Thyroid Cancer | Unknown | The Leeds Teaching Hospitals NHS Trust | 10 | 2021-02-01 | 2021-02-18 | |
| Thermal Ablation of Cervical Metastases From Thyroid Carcinoma Laser ablation, Cryoablation, Radiofrequency ablation - Thyroid Neoplasia, Well-Differentiated Thyroid Cancer | Not applicable | Completed | Instituto do Cancer do Estado de São Paulo | 84 | 2020-12-22 | 2026-09-22 |
| A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation Selpercatinib - Solid Tumor, Medullary Thyroid Cancer | Phase 2 | Active not recruiting | Eli Lilly and Company | 77 | 2020-03-16 | 2026-08-07 |
| A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer Selpercatinib, Cabozantinib, Vandetanib - Medullary Thyroid Cancer | Phase 3 | Active not recruiting | Loxo Oncology, Inc. | 291 | 2020-02-11 | 2026-03-19 |
| Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations TPX-0046 - Non Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Terminated | Turning Point Therapeutics, Inc. | 41 | 2019-12-06 | 2024-06-13 |
| Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer Ponatinib - Medullary Thyroid Cancer | Phase 2 | Withdrawn | Antonio Fojo | 2019-07-26 | 2021-10-13 | |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors Selpercatinib - Medullary Thyroid Cancer, Infantile Myofibromatosis | Phase 1 / Phase 2 | Active not recruiting | Eli Lilly and Company | 36 | 2019-06-13 | 2026-01-06 |
| A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) LOXO-292 - Non-Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Active not recruiting | Eli Lilly and Company | 857 | 2017-05-02 | 2026-04-16 |
Showing 20 of 40. Sign in to see all of them.
Carcinoma, Medullary (40) · Thyroid Neoplasms (10) · Carcinoma, Non-Small-Cell Lung (9) · Colonic Neoplasms (5) · Lung Neoplasms (4) · Neoplasms (4) · Neuroendocrine Tumors (4) · Thyroid Cancer, Papillary (4) · Breast Neoplasms (3) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Head and Neck Neoplasms (3) · Lung Diseases (3)
Neoplasms, Ductal, Lobular, and Medullary (40) · Adenocarcinoma (39) · Carcinoma (39) · Carcinoma, Neuroendocrine (39) · Neoplasms by Histologic Type (39) · Neoplasms, Germ Cell and Embryonal (39) · Neoplasms, Glandular and Epithelial (39) · Neoplasms, Nerve Tissue (39) · Neuroectodermal Tumors (39) · Neoplasms (36) · Neuroendocrine Tumors (36) · Neoplasms by Site (15) · Endocrine Gland Neoplasms (11) · Endocrine System Diseases (11) · Head and Neck Neoplasms (8)
selpercatinib (5) · cabozantinib (4) · vandetanib (4) · pralsetinib (3) · Calcium Aluminosilicate (1) · Cryoelectron Microscopy (1) · Cryosurgery (1) · Dexamethasone (1) · Everolimus (1) · Ga(III)-DOTATOC (1) · Laser Therapy (1) · Lithium Carbonate (1) · Lutetium-177 (1) · Omeprazole (1) · Radiofrequency Ablation (1)
Eli Lilly and Company (4) · Exelixis (2) · Hoffmann-La Roche (2) · Sanofi (2) · AbbVie (1) · Antonio Fojo (1) · Aristotle University Of Thessaloniki (1) · Blueprint Medicines Corporation (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Federico II University (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Genzyme, a Sanofi Company (1) · Icahn School of Medicine at Mount Sinai (1) · Institut Claudius Regaud (1)
United States (18) · China (10) · Italy (10) · France (8) · Spain (8) · South Korea (7) · Australia (6) · Canada (6) · Germany (6) · United Kingdom (6) · Brazil (5) · Israel (5) · Poland (5) · Belgium (4) · Japan (4)
Annamaria Colao (1) · Antonio Fojo, MD (1) · Charles Hsu, MD (1) · Fernanda Vaisman, MD, PhD (1) · Herbert Chen, MD (1) · James Moor, FRCS (1) · Johannes Czernin, MD (1)
PMID 36657661, PMID 37934000, PMID 25117183, PMID 28473600, PMID 29572709, PMID 32372416, PMID 32846060, PMID 32846061, PMID 34088726, PMID 34118197, PMID 34118198, PMID 34292174, PMID 35403447, PMID 35715405, PMID 35923928, PMID 35930972, PMID 35962206, PMID 35969032, PMID 36056624, PMID 36062046, PMID 36108661, PMID 36122315, PMID 36996322, PMID 37265412, PMID 37282666, PMID 37315261, PMID 37655205, PMID 37870969, PMID 37916501, PMID 38009200, PMID 38661071, PMID 39085487, PMID 39094065, PMID 39471424, PMID 39489747, PMID 39694978, PMID 39759832, PMID 39983053, PMID 40617171, PMID 40639400, PMID 41886723, PMID 42337037, PMID 42874021
2019 (2), 2016 (1), 2017 (1), 2023 (1), R01CA300202 (1)